Journal article
Tumor Response and Symptom Palliation from RAINBOW, a Phase III Trial of Ramucirumab Plus Paclitaxel in Previously Treated Advanced Gastric Cancer.
Stefano Cascinu, György Bodoky, Kei Muro, Eric Van Cutsem, Sang Cheul Oh, Gunnar Folprecht, Sumitra Ananda, Gustavo Girotto, Zev A Wainberg, Maria Luisa Limon Miron, Jaffer Ajani, Ran Wei, Astra M Liepa, Roberto Carlesi, Michael Emig, Atsushi Ohtsu
The Oncologist | Published : 2021
DOI: 10.1002/onco.13623
Abstract
BACKGROUND: In the intent-to-treat (ITT) population of the RAINBOW study, objective response rate (ORR) was 28% and 16% in the ramucirumab and control arms, respectively. To further characterize tumor response, we present details on timing and extent of tumor shrinkage, as well as associations with symptom palliation. MATERIALS AND METHODS: Tumor response was assessed with RECIST v1.1, and quality of life (QoL) was assessed with the European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire-Core 30 (EORTC QLQ-C30) v3.0. Prespecified and post hoc analyses were conducted in the ITT population, patients with measurable disease, or responders, and included best over..
View full abstract